Daniel Shinners, MD
Pulmonary Disease · Baltimore, MDNPI 1205877552
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 726 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations.
Across 726 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Boehringer Ingelheim$1K
- Grifols USA, LLC$845
- Takeda Pharmaceuticals U.S.A., Inc.$685
- plus $6K from 43 others
Across 2 payments — averaging $6750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$14K
What the payments were for
- Food & beverage$14,45097%
- Education$911%
- Entertainment$2812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,822 in reported general payments places this provider in the 85th percentile of 297 pulmonary disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 358 | $367,784 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 140 | $103,688 |
| Breo ElliptaFluticasone/Vilanterol | 155 | $85,202 |
| TezspireTezepelumab-Ekko | 19 | $82,269 |
| Dupixent PenDupilumab | 12 | $50,038 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 69 | $50,035 |
| Incruse ElliptaUmeclidinium Bromide | 56 | $31,980 |
| Arnuity ElliptaFluticasone Furoate | 80 | $23,086 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $16,366 |
| Spiriva RespimatTiotropium Bromide | 22 | $15,988 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 391 | $12,804 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $11,119 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 74 | $10,573 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 18 | $10,174 |
| Wixela InhubFluticasone Propion/Salmeterol | 56 | $9,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $3,188 | $611,739789 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Bevespi Aerosphere, Pulmicort Flexhaler | $2,190 | $147,781123 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,005 | $39,44754 claims |
| Teva Pharmaceuticals USA, Inc.Proair Respiclick | $104 | $75213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 297 pulmonary disease providers in Maryland.
Other pulmonary disease in Baltimore
- Alan SchwartzBaltimore$1.3M
- Hitesh BatraBaltimore$611K
- Lonny YarmusBaltimore$582K
- Robert WiseBaltimore$389K
- Ko Pen WangBaltimore$280K
- Hans LeeBaltimore$277K
- Angela ArgentoBaltimore$269K
- Michael DrummondBaltimore$263K
- Jason AkulianBaltimore$231K
- Kathryn RobinettBaltimore$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.